of this report and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “ Exchange Act ” ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Director — James Daly: The filing discloses the routine election of a new director to the board, which is a standard governance event and not an executive departure.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Any shares of the Company’s common stock that may be issued upon conversion of the Convertible Notes will be issued in reliance upon Section 3(a)(9) of the Securities Act as involving an exchange by the Company exclusively with its security holders. Initially, a maximum of 13,676,100 shares of the Company’s common stock may be issued upon conversion of the Convertible Notes, based on the initial maximum conversion rate of 9.1174 shares of common stock per $1,000 principal amount of Convertibl…

Entry into a Material Definitive Agreement. Convertible Notes Indentures On September 22, 2026, Halozyme Therapeutics, Inc. (the “Company,” “we,” “us” or “our”) completed its previously announced sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033 (the “Convertible Notes”), including $200.0 million in aggregate principal amount of its Convertible Notes purchased pursuant to the exercise by the initial purchasers (the “Initial Purchasers”) of the Conv…

Other Events On September 17, 2026, Halozyme Therapeutics, Inc. (the “Company”) issued a press release announcing the pricing of its offering of $1.3 billion aggregate principal amount of convertible senior notes due 2033 (the “Convertible Notes”). The Company also granted a 13-day option to the initial purchasers to purchase up to an additional $200 million aggregate principal amount of the Convertible Notes. The Convertible Notes are being offered and sold only to persons reasonably believe…

Other Events On September 16, 2026, Halozyme Therapeutics, Inc. (the “Company”) issued a press release announcing that it proposes to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the “Convertible Notes”). The Company also expects to grant a 13-day option to the initial purchasers to purchase up to an additional $150 million aggregate principal amount of the Convertible Notes. A copy of the press release i…

Director — Dannielle Appelhans: The filing discloses the election of a new director to the board, which is a routine governance event and not a departure of a senior executive.

of this report and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “ Exchange Act ” ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Senior Vice President, Chief Operating Officer — Cortney Caudill: Ms. Caudill departed from her role as Senior Vice President, Chief Operating Officer.

of this report and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “ Exchange Act ” ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

CFO — Darren Snellgrove: The company hired a new CFO from an external source with significant experience.

Interim Chief Financial Officer (Interim CFO) — David Ramsay: David Ramsay has been appointed as the Interim Chief Financial Officer.

of this report and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “ Exchange Act ” ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Results of Operations and Financial Condition. On January 28, 2026, Halozyme Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release containing information related to the Company’s 2026 financial guidance (the “Press Release”). The Press Release included certain preliminary, unaudited estimates regarding the Company’s financial results for the year ended December 31, 2025 (together with the preliminary estimates set forth below, the “Preliminary 2025 Estimates”). A c…

CEO — Dr. Helen Torley: The filing discloses a significant one-time performance-based equity grant to the CEO for retention and incentive purposes, not a change in management status or departure.

Director — James Lang: The filing discloses the election of a new director to the board, which is a standard governance event and not a departure of a senior executive.

CFO — Nicole LaBrosse: The CFO is departing to pursue a new opportunity under a transition plan with a defined separation date, representing a genuine loss of a senior executive.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Entry into a Material Definitive Agreement Convertible Notes Indentures On November 12, 2025, Halozyme Therapeutics, Inc. (the “ Company ,” “ we ,” “ us ” or “ our ”) completed its previously announced sale of $1,500.0 million aggregate principal amount convertible senior notes, consisting of (i) $750.0 million of 0% Convertible Senior Notes due 2031 (the “ 2031 Convertible Notes ”), including $100.0 million in aggregate principal amount of its 2031 Convertible Notes purchased pursuant to the…

Unregistered Sales of Equity Securities The information set forth in

Other Events. On November 6, 2025, Halozyme Therapeutics, Inc. (the “Company”) issued a press release announcing the pricing of its offering of $650.0 million aggregate principal amount of convertible senior notes due 2031 (the “2031 Notes”) and $650.0 million aggregate principal amount of convertible senior notes due 2032 (the “2032 Notes” and, together with the 2031 Notes, the “Convertible Notes”). The Company also granted a 13-day option to the initial purchasers to purchase up to an addit…

Entry into a Material Definitive Agreement. On November 5, 2025, Halozyme Therapeutics, Inc. (the “Company”), Halozyme, Inc. (“Halozyme”) and certain other subsidiaries of the Company entered into an Amendment No. 3 (the “Amendment”) to the Company’s Credit Agreement, dated as of May 24, 2022 (as previously amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”; capitalized terms used but not defined herein shall have the meanings…

Other Events. On November 5, 2025, the Company issued a press release announcing that it proposes to offer, subject to market conditions and other factors, $650.0 million aggregate principal amount of convertible senior notes due 2031 (the “2031 Notes”) and $650.0 million aggregate principal amount of convertible senior notes due 2032 (the “2032 Notes”). The Company also expects to grant a 13-day option to the initial purchasers to purchase up to an additional $100.0 million aggregate princip…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in